Scientists from Cuba and Mexico are collaborating on a groundbreaking molecule that could revolutionize treatment and therapy for Alzheimer’s disease. The molecule, known as Cneuro-201, has shown promising results in disaggregating amyloid plaques and inhibiting the aggregation of amyloid peptides in the brain.
Mitchell Valdés, the general director of the Cuban Neuroscience Center (Cneuro), stated that the Cneuro-201 molecule has demonstrated strong neuroprotective properties and has the ability to cross the blood-brain barrier to target amyloid plaques characteristic of Alzheimer’s disease. Researchers are now working on developing a mathematical model to design an effective and safe dosing regimen for human trials.
The study involves collaboration between the Center for Research and Advanced Studies of the National Polytechnic Institute, the National Autonomous University of Mexico (Unam), and the Institute of Neurobiology, with support from the National Council of Humanities, Science, and Technology of Mexico. Additionally, the UNAM Faculty of Medicine is working on early diagnosis methods for Alzheimer’s using the Cuban radiopharmaceutical Cneuro-120.
Alzheimer’s disease, first described by German neurologist Alois Alzheimer in 1906, currently affects millions of people worldwide. In Cuba alone, around 160,000 individuals suffer from this debilitating form of dementia that progressively destroys memory and cognitive function.
The collaboration between Cuban and Mexican scientists offers hope for advancing research and treatment options for Alzheimer’s disease, offering potential relief for countless individuals and families affected by this devastating condition.